Self-reported health outcomes in patients with psoriasis and psoriatic arthritis randomized to two etanercept regimens

Journal of the European Academy of Dermatology and Venereology

Volumn 26, Issue 11, 2012, Pages 1436-1443

  Gniadecki, R ^a   Robertson, D ^b   Molta, C T ^b   Freundlich, B ^b   Pedersen, R ^b   Li, W ^b   Boggs, R ^b   Zbrozek, A S ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HEALTH STATUS; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; TREATMENT OUTCOME; VISUAL ANALOG SCALE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; DOUBLE-BLIND METHOD; HUMANS; IMMUNOGLOBULIN G; PSORIASIS; QUALITY OF LIFE; RECEPTORS, TUMOR NECROSIS FACTOR; SELF DISCLOSURE;

EID: 84867575056     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2011.04308.x     Document Type: Article

References (37)

1. Gladman DD,. Psoriatic arthritis. Dermatol Ther 2004; 17: 350-363. (Pubitemid 39390589)
2. Feuchtenberger M, Kleinert S, Tony HP, Kneitz C,. Psoriatic arthritis: therapeutic principles. Clin Dermatol 2008; 26: 460-463.
3. Saad AA, Symmons DP, Noyce PR, Ashcroft DM,. Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials. J Rheumatol 2008; 35: 883-890. (Pubitemid 351747132)
4. Mease P,. Management of psoriatic arthritis: the therapeutic interface between rheumatology and dermatology. Curr Rheumatol Rep 2006; 8: 348-354. (Pubitemid 44638827)
5. Gottlieb AB, Chao C, Dann F,. Psoriasis comorbidities. J Dermatol Treat 2008; 19: 5-21. (Pubitemid 351252710)
6. Husted JA, Gladman DD, Farewell VT, et al. Validating the SF-36 health survey questionnaire in patients with psoriatic arthritis. J Rheumatol 1997; 24: 511-517. (Pubitemid 27153417)
7. Krueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001; 137: 280-284. (Pubitemid 32240779)
8. Gladman DD, Shuckett R, Russell ML, et al. Psoriatic arthritis (PSA)-an analysis of 220 patients. Q J Med 1987; 62: 127-141. (Pubitemid 17042878)
9. Gupta MA, Gupta AK,. Psoriasis and sex: a study of moderately to severely affected patients. Int J Dermatol 1997; 36: 259-262. (Pubitemid 27242616)
10. Ritchlin CT, Kavanaugh A, Gladman DD, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009; 68: 1387-1394.
11. Reich K, Mrowietz U,. Treatment goals in psoriasis. JDDG 2007; 5: 566-574. (Pubitemid 47047228)
12. Sterry W, Ortonne JP, Kirkham B, et al. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ 2010; 340: c147.
13. Finlay AY, Khan GK,. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-216. (Pubitemid 24194579)
14. The EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199-208.
15. Bjelland I, Dahl AA, Haug TT, Neckelmann D,. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res 2002; 52: 69-77. (Pubitemid 34192886)
16. Bruce B, Fries JF,. The Stanford Health Assessment Questionnaire: a review of its history, issues, progress, and documentation. J Rheumatol 2003; 30: 167-178. (Pubitemid 36077790)
17. Shikiar R, Willian MK, Okun MM, et al. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study. Health Qual Life Outcomes 2006; 4: 71.
18. O'Brien BJ, Drummond MF,. Statistical versus quantitative significance in the socioeconomic evaluation of medicines. Pharmacoeconomics 1994; 5: 389-398.
19. Kind P, Hardman G, Marcan S,. Population Norms for EQ-5D. Nov. Report No. 172. University of York, York, UK, 1999. Center for Health Economics Discussion Paper Series. 1999.
20. Mease PJ, Ganguly R, Wanke L, et al. How much improvement in functional status is considered important by patients with active psoriatic arthritis: applying the outcome measures in rheumatoid arthritis clinical trials? (OMERACT) group guidelines [abstract]. Ann Rheum Dis 2004; 63: 391.
21. Reich K, Segaert S, van de Kerkhof P, et al. Once-weekly administration of etanercept 50 mg improves patient-reported outcomes in patients with moderate-to-severe plaque psoriasis. Dermatology 2009; 219: 239-249.
22. Lubeck DP,. Patient-reported outcomes and their role in the assessment of rheumatoid arthritis. Pharmacoeconomics 2004; 22: 27-38. (Pubitemid 38269931)
23. Husted JA, Gladman DD, Farewell VT, Cook RJ,. Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. Arthritis Rheum 2001; 45: 151-158. (Pubitemid 32954441)
24. Sokoll KB, Helliwell PS,. Comparison of disability and quality of life in rheumatoid and psoriatic arthritis. J Rheumatol 2001; 28: 1842-1846. (Pubitemid 32726931)
25. Lundberg L, Johannesson M, Silverdahl M, et al. Health-related quality of life in patients with psoriasis and atopic dermatitis measured with SF-36, DLQI and a subjective measure of disease activity. Acta Derm Venereol 2000; 80: 430-434. (Pubitemid 32156226)
26. Zachariae H, Zachariae R, Blomqvist K, et al. Quality of life and prevalence of arthritis reported by 5,795 members of the Nordic Psoriasis Associations. Data from the Nordic Quality of Life Study. Acta Derm Venereol 2002; 82: 108-113. (Pubitemid 34596683)
27. Daudén E, Griffiths CEM, Ortonne J-P, et al. Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study. JEADV 2009; 23: 1374-1382.
28. Lillegraven S, Kvien TK,. Measuring disability and quality of life in established rheumatoid arthritis. Best Pract Res Clin Rheumatol 2007; 21: 827-840. (Pubitemid 47377806)
29. Emery P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008; 372: 375-382.
30. Spinhoven PH, Ormel J, Sloekers PPA, et al. A validation study of the Hospital Anxiety and Depression Scale (HADS) in different groups of Dutch subjects. Psychol Med 1997; 27: 363-370. (Pubitemid 27139969)
31. Kosinski M, Zhao SZ, Dedhiya S, et al. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum 2000; 43: 1478-1487. (Pubitemid 30452465)
32. van Riel PL, Freundlich B, MacPeek D, et al. Patient-reported health outcomes in a trial of etanercept monotherapy versus combination therapy with etanercept and methotrexate for rheumatoid arthritis: the ADORE trial. Ann Rheum Dis 2008; 67: 1104-1110.
33. Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004; 50: 2264-2272. (Pubitemid 38924405)
34. Ware JE, Kosinski M,. SF-36 Physical and Mental Health Summary Scales: a Manual for Users of Version 1. Quality Metric Inc., Lincoln, RI, 2001: 2001.
35. Gladman DD, Mease PJ, Cifaldi MA, et al. Adalimumab improves joint-related and skin-related functional impariment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial. Ann Rheum Dis 2007; 66: 163-168. (Pubitemid 46226048)
36. Kavanaugh A, Antoni C, Krueger GG, et al. Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis. Ann Rheum Dis 2006; 65: 471-477.
37. Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin 12/23 monocolonal antibody, for psoriatic arthritis: randomised double-blind, placebo-controlled, crossover trial. Lancet 2009; 373: 633-640.